-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Cytokinetics, Maintains $95 Price Target

Benzinga·01/21/2026 14:47:25
Listen to the news
RBC Capital analyst Leonid Timashev reiterates Cytokinetics (NASDAQ:CYTK) with a Outperform and maintains $95 price target.